Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IMDS nasdaq bulletin board -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (3033)	3/29/1999 2:30:00 PM
From: kenita	Respond to of 4122

Quote from Miami Herald February 22, 1999: "Considering that IDS has yet to sell a single machine, the Grables also draw lucrative salaries and stock options. According to company documents filed with the SEC, Richard Grable received $286,000 in salary in 1998 and options to buy 500,000 shares of IDS stock for 31 cents a share, worth $100,000 as of Friday. The year before, Grable earned $673,000 in cash and stock. Linda Grable received $119,000 in 1998 and the same option package as her husband. Grable said he, his wife and executives are, if anything, underpaid, given the amount of work they do."

To: gao seng who wrote (3033)	3/30/1999 8:34:00 AM
From: kenita	Read Replies (1) \| Respond to of 4122

From Diane Striat's affitdavit: "I telephoned Michael E. Marcarelli FDA/CDRH after having been referred to him by Andrew Skolnick " It is no secret I contacted Andrew Skolnick. I knew from Richard Grables' own words that the company was concerned about Andrew and his investigative reporting style. The company would dread any public question / answer period (like the RSNA) for fear that Andrew Skolnick would ask pertinent questions about the company's technology and past history. Those sort of questions would required honest answers in real time,giving Richard no time to be the "spin doctor" Richard Grable was intent on submitting those altered images to the FDA and the SEC. According to Kerin Eberle, investigating agent for the FDA, he did.